This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonati, A. Articles by Pelicci, P. G. Search for Related Content PubMed PubMed Citation Articles by Bonati, A. Articles by Pelicci, P. G.

Selective Expression and Constitutive Phosphorylation of SHC Proteins in the CD34⁺ Fraction of Chronic Myelogenous Leukemias¹

The Institute of Medical Pathology [A. B., P. L., R. A., S. P., P. P. D., P. G. P.] and Chair of Haematology [C. C-S., G. S., B. S.], University of Parma, 43100 Parma; European Institute of Oncology, 20141 Milan [E. M., P. G. P.]; and Chair of Haematology, University of Perugia, 06100 Perugia [A. T.], Italy

The BCR/ABL fusion protein is a constitutively active tyrosine kinase that is responsible for the pathogenesis of chronic myelogenous leukemia (CML). Clinically, CML is characterized by a chronic phase (CP) that eventually terminates into a blast crisis (BC). BC transformation is associated with accumulation of CD34⁺ blasts. We investigated the expression and phosphorylation of Src-homology-2 and collagen-homology domains (Shc) proteins in subpopulations of CML primary cells. Shc polypeptides are tyrosine kinase substrates that are constitutively tyrosine-phosphorylated in continuous cell lines of CML origin. High levels of Shc expression were found in the CD34⁺ cells from CML-BC, CML-CP and normal bone marrow. In contrast, CD34^- fractions from CML-CP and normal bone marrow expressed low levels of p46^Shc. Shc proteins were constitutively phosphorylated in the CD34⁺ fractions from CML cells (both CP and BC), but not in normal CD34⁺ cells. These data bear implications for the role of Shc in normal hemopoiesis and CML leukemogenesis: (a) dramatic changes of Shc expression during terminal differentiation of hemopoietic cells adds a further level of regulation to the signal transduction function of Shc; and (b) constitutive Shc tyrosine-phosphorylation in the rare CD34⁺ cells of CML-CP might contribute to the selection of this subpopulation during the blast crisis transformation of CMLs.

This article has been cited by other articles:

				P. Lunghi, A. Costanzo, M. Levrero, and A. Bonati Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells Blood, July 15, 2004; 104(2): 519 - 525. [Abstract] [Full Text] [PDF]